ATE319476T1 - Neuartige nicht pyrogene bakterienstämme und ihre verwendung - Google Patents

Neuartige nicht pyrogene bakterienstämme und ihre verwendung

Info

Publication number
ATE319476T1
ATE319476T1 AT96945937T AT96945937T ATE319476T1 AT E319476 T1 ATE319476 T1 AT E319476T1 AT 96945937 T AT96945937 T AT 96945937T AT 96945937 T AT96945937 T AT 96945937T AT E319476 T1 ATE319476 T1 AT E319476T1
Authority
AT
Austria
Prior art keywords
pyrogenic
strains
present
preparation
relates
Prior art date
Application number
AT96945937T
Other languages
English (en)
Inventor
David M Hone
Robert J Powell
Original Assignee
David M Hone
Robert J Powell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by David M Hone, Robert J Powell filed Critical David M Hone
Application granted granted Critical
Publication of ATE319476T1 publication Critical patent/ATE319476T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT96945937T 1995-11-22 1996-11-22 Neuartige nicht pyrogene bakterienstämme und ihre verwendung ATE319476T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US747895P 1995-11-22 1995-11-22

Publications (1)

Publication Number Publication Date
ATE319476T1 true ATE319476T1 (de) 2006-03-15

Family

ID=21726420

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96945937T ATE319476T1 (de) 1995-11-22 1996-11-22 Neuartige nicht pyrogene bakterienstämme und ihre verwendung

Country Status (6)

Country Link
US (2) US5997881A (de)
EP (1) EP0841941B1 (de)
AT (1) ATE319476T1 (de)
AU (1) AU2278497A (de)
DE (1) DE69635907D1 (de)
WO (1) WO1997018837A1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM399594A0 (en) * 1994-02-21 1994-03-17 Csl Limited Antigenic preparation for treatment or prevention of helicobacter infection
US5997881A (en) * 1995-11-22 1999-12-07 University Of Maryland, Baltimore Method of making non-pyrogenic lipopolysaccharide or A
US6887483B2 (en) * 1995-12-01 2005-05-03 University Of Iowa Research Foundation Non-toxic mutants of pathogenic gram-negative bacteria
US6080849A (en) * 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
CN1253551C (zh) * 1997-09-10 2006-04-26 维昂药品公司 减毒的遗传修饰肿瘤靶向细菌
US6368604B1 (en) 1997-09-26 2002-04-09 University Of Maryland Biotechnology Institute Non-pyrogenic derivatives of lipid A
KR20010075047A (ko) * 1998-09-11 2001-08-09 추후제출 2-케토-엘-굴론산 제조용 박테리아 균주
DE19844191A1 (de) * 1998-09-28 2000-03-30 Pharma Zentrale Gmbh Lipopolysaccharide aus Escherichia coli
AU1431101A (en) * 1999-10-04 2001-05-10 University Of Maryland Biotechnology Institute Novel adjuvant comprising a lipopolysaccharide antagonist
US6962696B1 (en) 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
AU7993600A (en) * 1999-10-04 2001-05-10 Sloan-Kettering Institute For Cancer Research Non-invasive tumor imaging by tumor-targeted bacteria
SK288007B6 (sk) 2000-06-29 2012-10-02 Glaxosmithkline Biologicals S. A. Multivalent vaccine composition, process for its producing, and its use
ATE525078T1 (de) * 2000-10-06 2011-10-15 Symbio Herborn Group Gmbh U Co Kyberdrug als autovakzine mit immunregulierenden wirkungen
ES2316492T3 (es) 2000-11-16 2009-04-16 Intervet International Bv Vacuna contra la salmonella.
US7015027B1 (en) 2001-11-20 2006-03-21 Mds (Canada) Inc. Radiation therapy by accumulation of therapeutic radionuclides in tumor-targeting bacteria
WO2004007444A2 (en) 2002-07-11 2004-01-22 Vicuron Pharmaceuticals, Inc. N-hydroxyamide derivatives possessing antibacterial activity
AU2003255279A1 (en) * 2002-08-16 2004-03-03 Johnson & Johnson Vision Care, Inc. Molds for producing contact lenses
WO2006015445A1 (en) 2004-08-13 2006-02-16 Marshall Barry J Bacterial delivery system
US8029777B2 (en) 2004-08-13 2011-10-04 Marshall Barry J Helicobacter system and uses thereof
EP1811832A4 (de) 2004-10-22 2009-12-30 Revivicor Inc Huftiere mit gentechnisch veränderten immunsystemen
US7766900B2 (en) 2005-02-21 2010-08-03 Biomet Manufacturing Corp. Method and apparatus for application of a fluid
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
EP2027272B1 (de) * 2006-05-24 2016-01-06 Scarab Genomics, LLC Plasmid-dna-zubereitungen und verfahren zu ihrer herstellung
US8795680B2 (en) * 2006-07-21 2014-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for conjugation of oligosaccharides or polysaccharides to protein carriers through oxime linkages via 3-deoxy-D-manno-octulsonic acid
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
US8518272B2 (en) 2008-04-04 2013-08-27 Biomet Biologics, Llc Sterile blood separating system
US8182769B2 (en) 2008-04-04 2012-05-22 Biomet Biologics, Llc Clean transportation system
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
HUE029265T2 (en) * 2008-10-27 2017-02-28 Glaxosmithkline Biologicals Sa Method of purifying carbohydrates from the group streptococci
WO2010051288A1 (en) 2008-10-27 2010-05-06 Revivicor, Inc. Immunocompromised ungulates
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
WO2010141143A2 (en) * 2009-04-21 2010-12-09 Vivocure, Inc. Engineered avirulent bacteria strains and use in medical treatments
WO2011031850A1 (en) 2009-09-10 2011-03-17 Merial Limited New vaccine formulations comprising saponin-containing adjuvants
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
EP2545023A4 (de) * 2010-02-15 2017-04-12 Abbvie Inc. Verfahren zur herstellung von scyllo-inositol
AU2011316540A1 (en) 2010-10-13 2014-04-10 Elan Pharmaceuticals, Inc. Methods of synthesis of scyllitol and related compounds
WO2012145577A1 (en) 2011-04-20 2012-10-26 Merial Limited Adjuvanted rabies vaccine with improved viscosity profile
AU2012278407B2 (en) 2011-07-07 2017-01-19 Intravacc B.V. A process for detergent-free production of outer membrane vesicles of a gram-negative bacterium
WO2013128288A1 (en) 2012-02-27 2013-09-06 Thelial Technologies S.A. Monomeric bacterial actin adp-ribosyltransferases as cancer chemotherapeutics
KR102214794B1 (ko) * 2013-01-02 2021-02-10 디코이 바이오시스템즈 인코퍼레이티드 박테리아를 사용하는 암 치료용 조성물 및 방법
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
WO2014138696A1 (en) 2013-03-07 2014-09-12 University Of Maryland, Baltimore Immunotherapeutic potential of modified lipooligosaccharides/lipid a
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
WO2016118336A1 (en) 2015-01-20 2016-07-28 Paw Bioscience Products, Inc. Pre-sterilized syringe system and method of use
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
JP6995045B2 (ja) * 2015-12-22 2022-02-04 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｌｐｓ抽出プロセス
EP3263695A1 (de) 2016-06-29 2018-01-03 GlaxoSmithKline Biologicals SA Immunogene zusammensetzungen
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
JP7097438B2 (ja) 2017-07-11 2022-07-07 アクティム・セラピューティクス・インコーポレイテッド 遺伝子操作された免疫刺激性細菌菌株およびその使用
KR20240067973A (ko) 2018-07-11 2024-05-17 액팀 테라퓨틱스, 인코퍼레이티드 조작된 면역자극성 박테리아 균주 및 이의 용도
EP3844276A2 (de) 2018-08-28 2021-07-07 Actym Therapeutics, Inc. Manipulierte immunstimulierende bakterienstämme und verwendungen davon
FI3856213T3 (fi) 2018-09-27 2024-05-30 Indaptus Therapeutics Inc Menetelmiä infektioiden hoitamiseksi bakteerien avulla
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
US12285437B2 (en) 2019-10-30 2025-04-29 The Research Foundation For The State University Of New York Reversing the undesirable pH-profile of doxorubicin via activation of a disubstituted maleamic acid prodrug at tumor acidity
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
WO2022152939A1 (en) 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595660A (en) * 1983-03-02 1986-06-17 University Of Delaware Molecular cloning with bifunctional plasmid vectors in Bacillus subtilis, mutants and substantially stably transformed mutants of Bacillus subtilis, and methods for utilizing the transformed mutants
US5561064A (en) * 1994-02-01 1996-10-01 Vical Incorporated Production of pharmaceutical-grade plasmid DNA
US5997881A (en) * 1995-11-22 1999-12-07 University Of Maryland, Baltimore Method of making non-pyrogenic lipopolysaccharide or A
US6887483B2 (en) * 1995-12-01 2005-05-03 University Of Iowa Research Foundation Non-toxic mutants of pathogenic gram-negative bacteria
WO1997025061A1 (en) * 1996-01-09 1997-07-17 Bristol-Myers Squibb Company De-myristolated lipopolysaccharide of gram-negative bacteria
US6080849A (en) * 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence

Also Published As

Publication number Publication date
EP0841941A1 (de) 1998-05-20
US6548287B1 (en) 2003-04-15
DE69635907D1 (de) 2006-05-04
EP0841941A4 (de) 2001-11-14
WO1997018837A1 (en) 1997-05-29
US5997881A (en) 1999-12-07
EP0841941B1 (de) 2006-03-08
AU2278497A (en) 1997-06-11

Similar Documents

Publication Publication Date Title
ATE319476T1 (de) Neuartige nicht pyrogene bakterienstämme und ihre verwendung
HUP9900920A2 (hu) Eljárás emlőssejt-tenyészetekben termelt proteinek szializációjának szabályozására
Neeser et al. In vitro modulation of oral bacterial adhesion to saliva‐coated hydroxyapatite beads by milk casein derivatives
EA200200517A1 (ru) Клеточная везикула, называемая "экзосома", ее получение и применение для стимуляции иммунного ответа
Huebner et al. Production of type-specific C antigen in virus-free hamster tumor cells induced by adenovirus type 12
BR9708387A (pt) Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada.
NO20000774D0 (no) Mutanter og gram-negative mukøse bakterier, og anvendelse derav i vaksiner
DE69637942D1 (de) Stimulationsfaktor für dendriten
Peterson et al. Trichomonas vaginalis is dependent on uptake and degradation of human low density lipoproteins.
DK0480949T4 (da) Fremstilling af virusvaccine
BR9811675A (pt) Genes isolados para proteìna da membrana de célula dentrìtica
KR890700030A (ko) 인플루엔자균(Haemophilus influenzae)의 백신 및 진단방법
KR100366482B1 (ko) 백신으로서 정제된 분류가능하지 않은 헤모필루스 인프루엔자 p5단백질, 및 그의 정제방법
BR0016212A (pt) Proteìna especìfica do cromossoma sexual e sequência de ácido nucleico isolada e purificada, método para identificar moléculas especìficas de cromossomas sexuais associadas com membranas celulares de esperma animal, anticorpo contra um epìtopo de uma molécula especìfica de cromossomas sexuais, métodos de triagem para uma molécula especifica de cromossomas sexuais, e para separar esperma determinante de macho e fêmea de sêmen nativo kit para executar um método, contraceptivo, proteìna especìfica do cromossoma sexual isolada e purificada, e , molécula
DK1192242T3 (da) Fremstilling af den lipiderede form af de peptidgylcan-associerede lipoproteiner af gramnegative bakterier
AU3379693A (en) Vaccines and diagnostic assays for haemophilus influenzae
Hale et al. Antigen-liposome modification of target cells as a method to alter their susceptibility to lysis by cytotoxic T lymphocytes.
EP0689596B1 (de) Stimulierung der immunantwort durch virales protein
Hale et al. Elicitation of anti-viral cytotoxic T lymphocytes with purified viral and H-2 antigens.
DE60138952D1 (de) 16836, ein mitglied der humanen phospholipase c familie und seine verwendungen
Berthon et al. Kinetics of the in vitro antibody response to transmissible gastroenteritis (TGE) virus from pig mesenteric lymph node cells, using the ELISASPOT and ELISA tests
Warfel et al. Macrophage membrane glycoproteins that bind Griffonia simplicifolia I‐B4: Effect on cytotoxicity and protein secretion
BR9814556A (pt) Cepas isoladas de staphylococcus aureus e vacinas fabricadas a partir das mesmas
Saunders et al. Humoral response of the mouse to Treponema pallidum.
DE60137222D1 (de) Humanes trp-ähnliches kalziumkanalprotein-2 tlcc-2

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties